» Authors » S Vallet

S Vallet

Explore the profile of S Vallet including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 637
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Semenova T, Nemoz B, Thibault V, Lagathu G, Duverlie G, Brochot E, et al.
Epidemiol Infect . 2019 Aug; 147:e234. PMID: 31364570
Treatment options for Hepatitis C infection have greatly improved with direct-acting antiviral (DAA) combinations achieving high cure rates. Nevertheless, the cost of this treatment is still high and access to...
2.
Bal A, Pichon M, Picard C, Casalegno J, Valette M, Schuffenecker I, et al.
BMC Infect Dis . 2018 Oct; 18(1):537. PMID: 30373528
Background: In recent years, metagenomic Next-Generation Sequencing (mNGS) has increasingly been used for an accurate assumption-free virological diagnosis. However, the systematic workflow evaluation on clinical respiratory samples and implementation of...
3.
Lambert-Niclot S, Grude M, Chaix M, Charpentier C, Reigadas S, Le Guillou-Guillemette H, et al.
J Antimicrob Chemother . 2018 May; 73(8):2147-2151. PMID: 29718247
Background: Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on...
4.
Rosenberger F, Wiskemann J, Vallet S, Haag G, Schembri E, Jager D, et al.
Support Care Cancer . 2017 Jul; 25(12):3655-3664. PMID: 28667563
Purpose: While there is growing evidence for positive effects of progressive resistance training in curatively treated cancer patients, data on advanced cancer patients are scarce. This pilot study aimed at...
5.
Assoumou L, Charpentier C, Recordon-Pinson P, Grude M, Pallier C, Morand-Joubert L, et al.
J Antimicrob Chemother . 2017 Mar; 72(6):1769-1773. PMID: 28333232
Background: Surveillance of HIV-1 resistance in treated patients with a detectable viral load (VL) is important to monitor, in order to assess the risk of spread of resistant viruses and...
6.
Fan F, Bashari M, Morelli E, Tonon G, Malvestiti S, Vallet S, et al.
Leukemia . 2016 Nov; 31(7):1570-1581. PMID: 27890927
Despite therapeutic advances, multiple myeloma (MM) remains an incurable disease, predominantly because of the development of drug resistance. The activator protein-1 (AP-1) transcription factor family has been implicated in a...
7.
Le Guillou-Guillemette H, Ducancelle A, Bertrais S, Lemaire C, Pivert A, Veillon P, et al.
J Clin Virol . 2015 Jul; 69:203-9. PMID: 26209408
Background: The NS5A protein of the hepatitis C virus has been shown to be involved in the development of hepatocellular carcinoma. Objectives: In a French multicenter study, we investigated the...
8.
Alexandre Y, Blay G, Boisrame-Gastrin S, Le Gall F, Hery-Arnaud G, Gouriou S, et al.
Med Mal Infect . 2013 Jul; 44(1):9-17. PMID: 23820129
Antibiotics, of which Fleming has identified the first representative, penicillin, in 1928, allowed dramatical improvement of the treatment of patients presenting with infectious diseases. However, once an antibiotic is used,...
9.
Scullen T, Santo L, Vallet S, Fulciniti M, Eda H, Cirstea D, et al.
Leukemia . 2013 Feb; 27(8):1715-21. PMID: 23417027
Given the prevalence of osteolytic bone disease in multiple myeloma (MM), novel therapies targeting bone microenvironment are essential. Previous studies have identified activin A to be of critical importance in...
10.
Wong K, Ng K, Ong K, Ng W, Shankar S, Mahadevan A, et al.
Neuropathol Appl Neurobiol . 2012 Jan; 38(5):443-53. PMID: 22236252
Aims: To investigate if two important epidemic viral encephalitis in children, Enterovirus 71 (EV71) encephalomyelitis and Japanese encephalitis (JE) whose clinical and pathological features may be nonspecific and overlapping, could...